1. Background {#sec97532}
=============

Primary dysmenorrhea is defined as a cyclic and painful cramps pelvic, occurring just before or during menstruation which deranges daily activities ([@A27032R1]). Primary dysmenorrhea is one of the most common gynecologic disorders in young women which may affect more than half of menstruating women ([@A27032R2]-[@A27032R4]). Prostaglandin production by ovulation is the main cause of primary dysmenorrhea ([@A27032R5], [@A27032R6]). Digestive disorders including nausea, vomiting and diarrhea are the symptoms associated with primary dysmenorrhea, which are known due to intestinal spasms during menstruation ([@A27032R7]). The prevalence of dysmenorrhea in different populations is 50 - 90% and in Iran it is 74 - 86.1% ([@A27032R8], [@A27032R9]). Primary dysmenorrhea is a common cause of absenteeism from work, education, or referral to physician, which may lead to decreased efficacy of occupation and education. Although dysmenorrhea is not life threatening, it could have adverse effects on quality of life ([@A27032R10]).

In the USA, the annual economic loss of dysmenorrhea is 600 million working hours and two billion dollars ([@A27032R11], [@A27032R12]). In a study of 664 school students in Egypt, about 75% of the students had dysmenorrhea, rated scanty in 55.3%, moderate in 30%, and severe in 14.7% ([@A27032R13]). In a study on female students, 42% had a sessions absence from teaching or daily activities due to dysmenorrhea. The study suggested that 50% of girls believed that dysmenorrhea impairs daily activities ([@A27032R14]). Several methods such as drugs (including oral contraceptive pills (OCP) consumption and nonsteroidal anti-inflammatory drugs \[NSAIDs\]), nonpharmacological treatments (including exercise, heat therapy, acupuncture, and trans-electrical nerve stimulation (TENS)), dietary supplements (vitamins E, B, C, and Ca, Mg) and medicinal herbal have been used for treatment of primary dysmenorrhea ([@A27032R15], [@A27032R16]). Synthetic drugs, especially in long-term administration, have side effects. Nausea, stomach irritation, ulcers, renal papillary necrosis, and decreased renal blood flow are the side effects of prostaglandin synthesis inhibitors ([@A27032R14]). On the other hand, most of the young women have no tendency to use hormones to reduce pain. Today, regarding the effects of chemical drugs and the usage of herbal medicine, as well as alternative and complementary therapies in treatment of diseases, many interested researchers have been drawn to this area. One of these herbal medicines and alternative therapies is cinnamon which has many applications in medicine, but has not been sufficiently documented.

2. Objectives {#sec97533}
=============

Despite of its high prevalence, dysmenorrhea has not been managed effectively. Therefore, due to the lack of comprehensive studies for treatment of digestive disorders accompanied with dysmenorrhea in Iran and because of the importance of economic and social aspects of dysmenorrhea and acceptability and availability of traditional medicines, the aim of this study was to assess the effects of cinnamon on menstrual bleeding and systemic symptoms (nausea and vomiting) with primary dysmenorrhea in a sample of Iranian female college students from Ilam University of Medical Sciences (west of Iran) during 2013 - 2014.

3. Patients and Methods {#sec97537}
=======================

This was a quasi-experimental study performed at Ilam University of Medical Sciences during 2013 - 2014. The statistical population included all female college students living in governmental dormitories. The sample size was calculated using the information obtained from a pilot study with 10 patients and [Equation 1](#EQ2743){ref-type="disp-formula"}:
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A simple random sampling design was used ([Figure 1](#fig18758){ref-type="fig"}). After getting a written permission from the School of Nursing and Midwifery, the researcher visited the students of dormitories and the study objectives were explained to them. Thereafter, from the interested students who had the inclusion criteria using simple random sampling of the number of the students, the residences were divided into two groups of placebo and cinnamon.

In a randomized double-blind trial, 76 female students received placebo (capsules contain starch three times a day (TDS), n = 38) or cinnamon (capsules containing 420 mg cinnamon, two capsules TDS, n = 38) in 24 hours during the first three days of the menstrual cycle. The order of use and the shapes of capsules were similar in the groups. The inclusion criteria were age 18 - 30, regular menstrual cycles, lack of chronic diseases, moderate primary dysmenorrhea, digestive disorder (nausea or vomiting) with primary dysmenorrhea, lack of pelvic inflammatory diseases, tumor or fibroma, lack of recent stressors, and BMI 19 - 26. The exclusion criteria were the use of oral contraceptive pill (OCP), receiving analgesics during the study period, and medical or herbal allergy. We used VAS to determine the severity of pain and nausea. The number of times of vomiting was counted and menstrual bleeding was assessed by counting the number of saturated pads. Pain intensity, nausea, vomiting and menstrual bleeding were monitored in the groups during the first 72 hours of cycle (first, second, and third days of menstruation). The pain severity was assessed in 1, 2, 3, 4, 8, 16, 24, 48 and 72 hours after the intervention. The nausea severity, vomiting and the amount of menstrual bleeding were assessed in 24, 48, and 72 hours after the intervention. The female college students' age, menarche age, length of menstrual cycle, level and duration of pain, and age of dysmenorrhea were recorded.

![Flow Chart](ircmj-17-04-27032-i001){#fig18758}

3.1. Ethical Consideration {#sec97534}
--------------------------

The study was approved by the Institutional Ethics Committee of Ilam University of Medical Sciences, Ilam, Iran, and informed consents were obtained from all the participants (ethical code/92/H/184, 13/Dec/2012). In addition, this study was registered at the Iranian Registry of Clinical Trials (IRCT2013122114668N2).

3.2. Validity and Reliability {#sec97535}
-----------------------------

VAS rating is a standard tool for evaluation of pain severity, rated from 0 to 10.0; 0 means no pain and 10 means the maximum pain in this scale. Regarding the severity of nausea, 0 means no nausea and 10 means the maximum nausea. To determine the validity of the questionnaire, content validity was used. The questionnaire was provided to 10 faculty members of Ilam University of Medical Sciences and was used after revision. To determine the reliability of the questionnaire, Cronbach's alpha test was used. The reliability of the questionnaire was determined 0.89.

3.3. Statistical Analysis {#sec97536}
-------------------------

The collected data were analyzed using the statistical software SPSS, version 16. (SPSS Inc., Chicago, IL., USA). Descriptive statistics, independent t-test, chi-square test, repeated measurement, Friedman test, and Man-Whitney were performed to analyze the results. P \< 0.05 was considered significant.

4. Results {#sec97538}
==========

Baseline characteristics of the participants are shown in [Table 1](#tbl25138){ref-type="table"}. None of the 76 enrolled females was withdrawn for any reason. Samples characteristics were not different among the groups (P \> 0.5) ([Table 1](#tbl25138){ref-type="table"}). According to Kolmogorov-Smirnov test, data distribution was normal and we used the parametric methods (P \> 0.05) ([Table 2](#tbl25139){ref-type="table"}).

Independent t-test showed that the mean pain severity score in the cinnamon group was less than the placebo group at various intervals (P \< 0.001) ([Table 3](#tbl25140){ref-type="table"}). The mean duration of pain in the cinnamon group was significantly less than the placebo group at various intervals (P \< 0.001) ([Table 4](#tbl25141){ref-type="table"}). Repeated measurement analysis showed that the mean pain score in the cinnamon group (P \< 0.001) and the placebo group (P = 0.001) were significantly different in various intervals. The mean amount of menstrual bleeding in the cinnamon group was significantly lower than the placebo group at various intervals (P \< 0.05, P \< 0.001) ([Table 5](#tbl25142){ref-type="table"}).

According to Friedman's test, the amount of menstrual bleeding in the cinnamon group was significantly different at various intervals (P \< 0.001) and not significantly different in the placebo group at various intervals (P = 0.21). The mean severity of nausea significantly decreased in the cinnamon group compared with the placebo group at various intervals (P \< 0.001 and P \< 0.05, respectively) ([Table 6](#tbl25143){ref-type="table"}). Repeated measurement test showed that the mean nausea score in the cinnamon group (P \< 0.001) and the placebo group (P = 0.03) were significantly different in various intervals. The frequencies of vomiting in the cinnamon group were less than the placebo group at various intervals (P \< 0.001, P \< 0.05) ([Table 6](#tbl25143){ref-type="table"}). The frequencies of vomiting in the cinnamon group (P \< 0.001) and the placebo group (P = 0.04) were significantly different in various intervals.

###### Baseline Characteristics of the Participants ^[a](#fn23507){ref-type="table-fn"}^

  Characteristic                Placebo (n = 38)   Cinnamon (n = 38)   P Value^[b](#fn23508){ref-type="table-fn"}^
  ----------------------------- ------------------ ------------------- ---------------------------------------------
  **Age, y**                    1.5 ± 21.3         1.1 ± 20.7          0.135
  **Age of menarche, y**        0.8 ± 13.4         0.8 ± 13.3          0.116
  **Cycle, d**                  1.5 ± 27.8         1.5 ± 27.4          0.487
  **Age of dysmenorrhea, y**    0.9 ± 14.6         0.5 ± 14.3          0.476
  **Duration of bleeding, d**   6.1 ± 1.1          1.3 ± 6.3           0.090

^a^ Values are presented as mean ± SD.

^b^ P \> 0.05.

###### Kolmogorov--Smirnov Test ^[a](#fn23509){ref-type="table-fn"}^

  Parameters                    K-S     P Value   Parameters      K-S     P Value   Parameters    K-S     P Value
  ----------------------------- ------- --------- --------------- ------- --------- ------------- ------- ---------
  **Age, y**                    0.796   0.555     Pain 8          0.813   0.638     Bleeding 24   0.629   0.429
  **Age of menarche, y**        0.913   0.386     Pain 16         0.504   0.368     Bleeding 48   0.819   0.338
  **Cycle, d**                  0.657   0.486     Pain 24         0.681   0.593     Bleeding 72   0.749   0.628
  **Age of dysmenorrhea, y**    0.589   0.674     Pain 48         0.938   0.654     Nausea        0.563   0.364
  **Duration of bleeding, d**   0.847   0.538     Pain72          0.727   0.433     Nausea 24     0.486   0.377
  **Pain**                      0.719   0.439     Pain duration   0.438   0.322     Nausea 48     0.538   0.467
  **Pain 1**                    0.691   0.518     Duration 24     0.549   0.738     Nausea 72     0.613   0.489
  **Pain 2**                    0.739   0.345     Duration 48     0.582   0.623     Vomiting 24   0.764   0.513
  **Pain 3**                    0.489   0.636     Duration 72     0.648   0.389     Vomiting 48   0.839   0.360
  **Pain 4**                    0.949   0.421     Bleeding        0.864   0.512     Vomiting 72   0.693   0.459

^a^Abbreviation: K-S, Kolmogorov--Smirnov.

###### Outcome of Severity of Pain Between Groups^[a](#fn23510){ref-type="table-fn"}^

  Pain Score by vas at Various Intervals, h   Placebo (n = 38)   Cinnamon (n = 38)   P Value
  ------------------------------------------- ------------------ ------------------- --------------------------------------------
  **Before treatment**                        1 ± 7.5            1 ± 7.4             0.569 ^[b](#fn23511){ref-type="table-fn"}^
  **1 h After intervention**                  7.3 ± 0.6          7.1 ± 0.7           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **2 h After intervention**                  7.1 ± 0.9          6.8 ± 0.7           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **3 h After intervention**                  6.8 ± 0.7          6.6 ± 0.4           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **4 h After intervention**                  6.7 ± 0.7          6.4 ± 0.6           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **8 h After intervention**                  6.5 ± 0.7          5.9 ± 0.9           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **16 h After intervention**                 6.3 ± 0.4          4.3 ± 0.7           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **24 h After intervention**                 6.1 ± 0.4          4.1 ± 0.5           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **48 h After intervention**                 5.3 ± 0.6          3.2 ± 0.6           0.00 ^[c](#fn23512){ref-type="table-fn"}^
  **72 h After intervention**                 4.0 ± 0.3          1.8 ± 0.4           0.00 ^[c](#fn23512){ref-type="table-fn"}^

^a^ Values are presented as mean ± SD.

^b^ P \> 0.05.

^c^ P \< 0.001.

###### Outcome of Duration of Pain Between Groups^[a](#fn23513){ref-type="table-fn"}^

  Duration of Pain, hour        Placebo (n = 38)   Cinnamon (n = 38)   P Value
  ----------------------------- ------------------ ------------------- --------------------------------------------
  **Before treatment**          2.3 ± 26.5         2.3 ± 27.2          0.359 ^[b](#fn23514){ref-type="table-fn"}^
  **24 h After intervention**   25.2 ± 1.9         16.5 ± 1.6          0.00 ^[c](#fn23515){ref-type="table-fn"}^
  **48 h After intervention**   21.2 ± 1.5         8.0 ± 0.9           0.00 ^[c](#fn23515){ref-type="table-fn"}^
  **72 h After intervention**   18.7 ± 1.3         3.2 ± 0.4           0.00 ^[c](#fn23515){ref-type="table-fn"}^

^a^ Values are presented as mean ± SD.

^b^ P \> 0.05.

^c^ P \< 0.001.

###### Outcome of the Amount of Menstrual Bleeding Between Groups ^[a](#fn23516){ref-type="table-fn"}^

  Amount of Menstrual Bleeding (Number of Used Pad)      Placebo (n = 38)   Cinnamon (n = 38)   P Value
  ------------------------------------------------------ ------------------ ------------------- --------------------------------------------
  **Amount of menstrual bleeding before of treatment**                                          
  Scanty (1 pad)                                         3 (7.8)            4 (10.5)            0.251 ^[b](#fn23517){ref-type="table-fn"}^
  Average (2-3 pads)                                     23 (60.5)          22 (57.8)           0.181 ^[b](#fn23517){ref-type="table-fn"}^
  Excessive (≥ 4 pads)                                   12 (31.5)          12 (31.5)           0.274 ^[b](#fn23517){ref-type="table-fn"}^
  **24 h After intervention**                                                                   
  Scanty (1 pad)                                         4 (10.5)           7 (18.4)            0.032 ^[c](#fn23518){ref-type="table-fn"}^
  Average (2-3 pads)                                     23 (60.5)          25 (65.7)           0.061 ^[b](#fn23517){ref-type="table-fn"}^
  Excessive (≥ 4 pads)                                   11 (28.9)          6 (15.7)            0.037 ^[c](#fn23518){ref-type="table-fn"}^
  **48 h After intervention**                                                                   
  Scanty (1 pad)                                         6 (15.7)           17 (44.7)           0.012 ^[c](#fn23518){ref-type="table-fn"}^
  Average (2-3 pads)                                     23 (60.5)          20 (52.6)           0.031 ^[c](#fn23518){ref-type="table-fn"}^
  Excessive (≥ 4 pads)                                   9 (23.6)           1 (2.6)             0.00 ^[d](#fn23519){ref-type="table-fn"}^
  **72 h After intervention**                                                                   
  Scanty (1 pad)                                         11 (18.4)          27 (71.05)          0.00 ^d^
  Average (2-3 pads)                                     23 (60.5)          11 (28.9)           0.00 ^[d](#fn23519){ref-type="table-fn"}^
  Excessive (≥ 4 pads)                                   3 (7.8)            0 (0.00)            0.00 ^[d](#fn23519){ref-type="table-fn"}^

^a^ Values are presented as No. (%).

^b^ P \> 0.05.

^c^ P \< 0.05.

^d^ P \< 0.001.

###### Outcome of Severity of Nausea and Vomiting Between Groups ^[a](#fn23520){ref-type="table-fn"},\ [b](#fn23521){ref-type="table-fn"}^

  Nausea Score by VAS at Various Intervals, h   Placebo (n = 38)   Cinnamon (n = 38)   P Value
  --------------------------------------------- ------------------ ------------------- -------------------------------------------
  **Nausea score before of treatment**          5.8 ± 2.1          5.6 ± 1.8           0.09
  **24 h After intervention**                   5.5 ± 1.9          4.1 ± 1.6           0.01 ^[c](#fn23522){ref-type="table-fn"}^
  **48 h After intervention**                   4.7 ± 2.2          2.6 ± 1.4           0.00 ^[d](#fn23523){ref-type="table-fn"}^
  **72 h After intervention**                   3.3 ± 1.6          0.5 ± 1.1           0.00 ^[d](#fn23523){ref-type="table-fn"}^
  **Number of vomiting**                                                               
  **Number of vomiting before of treatment**                                           
  non                                           25 (65.7)          26 (68.4)           0.06^[e](#fn23524){ref-type="table-fn"}^
  1-2                                           11 (28.9)          10 (26.3)           0.18^[e](#fn23524){ref-type="table-fn"}^
  ≥ 3                                           2 (5.2)            2 (5.2)             0.08^[e](#fn23524){ref-type="table-fn"}^
  **24 h After intervention**                                                          
  non                                           26 (68.4)          32 84.2)            0.01 ^[c](#fn23522){ref-type="table-fn"}^
  1-2                                           10 (26.3%)         5 (13.1)            0.00 ^[d](#fn23523){ref-type="table-fn"}^
  ≥ 3                                           2 (5.2%)           1 (2.6)             0.04 ^[c](#fn23522){ref-type="table-fn"}^
  **48 h After intervention**                                                          
  non                                           29 (76.3)          36 (94.7)           0.00 ^[d](#fn23523){ref-type="table-fn"}^
  1-2                                           7 (18.4)           2 (5.2)             0.00 ^[d](#fn23523){ref-type="table-fn"}^
  ≥ 3                                           2 (5.2)            0 (0.00)            0.00 ^[d](#fn23523){ref-type="table-fn"}^
  **72 h After intervention**                                                          
  non                                           31 (81.5)          38 (100)            0.00 ^[d](#fn23523){ref-type="table-fn"}^
  1-2                                           7 (18.4)           0 (0.00)            0.00 ^[d](#fn23523){ref-type="table-fn"}^
  ≥ 3                                           0 (0.00)           0 (0.00)            0.00

^a^Abbreviation: VAS, Visual analogue scale.

^b^Values are presented as mean ± SD or No. (%).

^c^ P \< 0.05.

^d^ P \< 0.001.

^e^P \> 0.05.

5. Discussion {#sec97539}
=============

Our results suggested that cinnamon significantly reduced pain, the amount of menstrual bleeding, nausea and vomiting in female college students. Therefore, cinnamon improves the severity of primary dysmenorrhea. This finding was consistent with the previous studies on the effects of herbal medicines such as cumin ([@A27032R16]) *thymus vulgaris*, *Achillea millefolium* ([@A27032R17]), fennel ([@A27032R18]), *Matricaria recutita* ([@A27032R19]), *Rosa damascena* extract ([@A27032R20]), aromatherapy massage and *Zingiber officinale* ([@A27032R1]) in treatment of dysmenorrhea.

Dysmenorrhea is a common problem in young females ([@A27032R21], [@A27032R22]). Primary dysmenorrhea is caused by an increase in the synthesis and release of prostaglandins, particularly PGF2α from the uterine endometrium during the menstrual period. This prostaglandin in turn causes contraction of smooth muscles in many adjacent tissues. Uterine smooth muscle contractions cause colicky pains, spasmodic and labor-like pains in the lower abdomen and cause lower back pain which is a characteristic of dysmenorrhea. Furthermore, prostaglandin secretion causes smooth muscle contraction of gastric-intestinal tract, which can lead to nausea, vomiting and diarrhea ([@A27032R7], [@A27032R23]-[@A27032R27]). Today in herbal medicine, numerous benefits have been found. Herbal medicines reduce the level of prostaglandins, have nitric oxide modulation effects, increase the levels of beta-endorphin, block calcium channels and improve circulation; thus, are effective in the treatment of dysmenorrhea ([@A27032R28]-[@A27032R30]). Cinnamon is one of the oldest and most traditional herbal medicines. Cinnamon is a member of the Lauraceae family, which has been widely used as a spice for thousands of years to improve the taste of foods and drinks. Indications of cinnamon in medicine include diarrhea treatment, as an astringent, germicide, antispasmodic, dyspeptic complaints, for chronic bronchitis, treatment of impotence, frigidity, dyspnea, inflammation of eye, leukorrhea, vaginitis, rheumatism, and neuralgia, as well as wounds and toothaches, cold and flu; but, has not been sufficiently documented. The oil extracted of cinnamon has anti-inflammatory activity, as a treatment for dysmenorrhea and to stop bleeding. However, toxicology trials performed with high doses demonstrated that the oil of this plant stimulated the mucous membranes and instigated hematuria ([@A27032R1], [@A27032R5]).

The main component of the essential oil of cinnamon bar is cinnamaldehyde (55 - 57%) and eugenol (5 - 18%). Cinnamaldehyde has been reported to have an antispasmodic effect. In addition, eugenol can prevent the biosynthesis of prostaglandins and reduce inflammation. Cinnamon contains a variety of vitamins such as vitamin A, thiamin, riboflavin, and ascorbic acid ([@A27032R20]). In adults and adolescents, 1.5 - 4 g daily of dried bark cinnamon can be used. In this study, we used a total dose of 2.52 g daily (in three divided doses), which was effective on primary dysmenorrhea and no side effects were found with this dose. On the other hand, this was the first clinical trial on the effects of cinnamon on menstrual bleeding and systemic symptoms including nausea and vomiting due to primary dysmenorrhea in female college students in Iran, which was the strength of this study. Some of the factors influencing pain intensity and other symptoms with primary dysmenorrhea such as culture, genetic and nutrition ([@A27032R20], [@A27032R31]) were uncontrollable, which were the weak points of this study.

In conclusion, this research suggested that cinnamon has a significant effect on reduction of pain, menstrual bleeding, nausea and vomiting due to primary dysmenorrhea, and with respect to no reported side effects, cinnamon can be regarded as a safe and effective treatment for primary dysmenorrhea.
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